Emerging data indicate that all‐oral antiviral treatments for chronic hepatitis C virus (HCV)
will become a reality in the near future. In replacing interferon‐based therapies, all‐oral …

We characterized hepatitis C virus (HCV) treatment knowledge, experience and barriers in a
cohort of community-based injection drug users (IDUs) in Baltimore, MD. In 2005, a …

Objectives We evaluated assessment and treatment for hepatitis C virus (HCV) among illicit
drug users accepting referral to a weekly HCV peer-support group at a multidisciplinary …

This review synthesized the literature for barriers to HCV antiviral treatment in persons with
HIV/HCV co-infection. Searches of PubMed, Embase, CINAHL, and Web of Science were …

Objective: To evaluate predictors and trends of referral for hepatitis C virus (HCV) care, clinic
attendance and treatment in an urban HIV clinic. Design and methods: A retrospective …

Injection drug use accounts for the majority of incident and prevalent cases of hepatitis C
virus (HCV) infection. However, very few injection drug users (IDUs) have received treatment …

Assessment and treatment for hepatitis C virus (HCV) in the community remains low. We
evaluated factors associated with HCV specialist assessment and treatment in a cross …

Objectives: We describe factors associated with and barriers to initiation of Direct Acting
Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis …

HIV/HCV co-infection is becoming one of the main causes of death in HIV+ persons. We
determined quality of life, clinical symptoms and health care utilization in HIV mono-infected …

Despite that the majority of hepatitis C virus (HCV) infection occurs among injection drug
users (IDUs), little is known about HCV treatment uptake in this group, particularly during …